RECURSION PHARMACEUTICALS, INC. Increase (Decrease) in Accounts Receivable
RECURSION PHARMACEUTICALS, INC. (RXRX) reported Increase (Decrease) in Accounts Receivable of -$114.00 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-23.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2022-03-23
- RECURSION PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for the quarter ending 2021-12-31 was $0.00.
- RECURSION PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for the quarter ending 2021-09-30 was -$16.00K, a 100.05% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for the quarter ending 2021-06-30 was -$13.00K.
- RECURSION PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for the quarter ending 2021-03-31 was -$85.00K.
- RECURSION PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for fiscal 2021 was -$114.00K, a 2380.00% decline from fiscal 2020.
- RECURSION PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for fiscal 2020 was $5.00K, a 81.48% decline from fiscal 2019.
- RECURSION PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for fiscal 2019 was $27.00K.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23 | -$16.00K derived: sum of 2 quarters · filed 2022-03-23 | -$29.00K derived: sum of 3 quarters · filed 2022-03-23 | -$114.00K 10-K · filed 2022-03-23 |
| 2021-09-30 | -$16.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$29.00K derived: sum of 2 quarters · filed 2021-11-10 | -$114.00K 10-Q · filed 2021-11-10 | -$30.16M derived: sum of 4 quarters · filed 2022-03-23 |
| 2021-06-30 | -$13.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | -$98.00K 10-Q · filed 2021-08-13 | -$30.14M derived: sum of 3 quarters · filed 2022-03-23 | $49.00K derived: sum of 4 quarters · filed 2022-03-23 |
| 2021-03-31 | -$85.00K 10-Q · filed 2021-05-12 | -$30.13M derived: sum of 2 quarters · filed 2022-03-23 | $62.00K derived: sum of 3 quarters · filed 2022-03-23 | $2.00K derived: sum of 4 quarters · filed 2022-03-23 |
| 2020-12-31 | -$30.04M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23 | $147.00K derived: sum of 2 quarters · filed 2022-03-23 | $87.00K derived: sum of 3 quarters · filed 2022-03-23 | $5.00K 10-K · filed 2022-03-23 |
| 2020-09-30 | $30.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $30.13M derived: sum of 2 quarters · filed 2021-11-10 | $30.05M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$60.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | -$142.00K 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | -$82.00K 10-Q · filed 2021-05-12 | |||
| 2019-12-31 | $27.00K 10-K · filed 2022-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |